Latest Glucagon-like peptide-1 analog Stories
PRINCETON, N.J., March 30 /PRNewswire-FirstCall/ -- Diabetes Care published online the results of the Novo Nordisk (NVO) LEAD(TM) 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily VictozaÂ®.
NEW ORLEANS, June 8 /PRNewswire/ -- Today, The Lancet published online the results of the Novo Nordisk (NVO) LEAD(TM) 6 study, a direct comparison between two products in a new class of diabetes treatments, the GLP-1 receptor agonists.
Amylin Pharmaceuticals Inc said Tuesday that it has sought approval from the US Food and Drug Administration (FDA) for its much-anticipated exenatide LAR, a once-weekly injectable diabetes treatment.
SILVER SPRING, Md., April 2 /PRNewswire-FirstCall/ -- Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) has finalized its discussions of questions related to liraglutide, a once-daily human GLP-1 analogue.
JERUSALEM, November 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc.
MONTREAL, Oct. 17 /PRNewswire-FirstCall/ -- Today, at the Canadian Diabetes Association Congress, physicians will get a first-time look at more detailed results from a phase 3b clinical study (LEAD(TM) 6) comparing the investigational new drug liraglutide to exenatide.
PRINCETON, N.J., Sept. 25 /PRNewswire/ -- Data from a 52-week phase 3 study (LEADTM 3) of Novo Nordisk's liraglutide, a once-daily human GLP-1 analog, were published online today in The Lancet.
Novo Nordisk has presented data from a Phase III clinical study that demonstrated adding the investigational new drug liraglutide, a human GLP-1 analog, to metformin and rosiglitazone in the treatment of type 2 diabetes, leads to improved blood glucose lowering, weight loss, blood pressure reduction and improvements in beta-cell functioning.